JP2021045150A5 - - Google Patents

Download PDF

Info

Publication number
JP2021045150A5
JP2021045150A5 JP2020197751A JP2020197751A JP2021045150A5 JP 2021045150 A5 JP2021045150 A5 JP 2021045150A5 JP 2020197751 A JP2020197751 A JP 2020197751A JP 2020197751 A JP2020197751 A JP 2020197751A JP 2021045150 A5 JP2021045150 A5 JP 2021045150A5
Authority
JP
Japan
Prior art keywords
seq
peptide
fragment
variant
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020197751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021045150A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021045150A publication Critical patent/JP2021045150A/ja
Publication of JP2021045150A5 publication Critical patent/JP2021045150A5/ja
Priority to JP2022203854A priority Critical patent/JP2023030082A/ja
Pending legal-status Critical Current

Links

JP2020197751A 2016-04-06 2020-11-30 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ Pending JP2021045150A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022203854A JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662319141P 2016-04-06 2016-04-06
GB1605872.9 2016-04-06
GB201605872 2016-04-06
US62/319,141 2016-04-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018552196A Division JP6989136B2 (ja) 2016-04-06 2017-04-05 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022203854A Division JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Publications (2)

Publication Number Publication Date
JP2021045150A JP2021045150A (ja) 2021-03-25
JP2021045150A5 true JP2021045150A5 (enExample) 2021-08-05

Family

ID=58503590

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552196A Expired - Fee Related JP6989136B2 (ja) 2016-04-06 2017-04-05 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2020197751A Pending JP2021045150A (ja) 2016-04-06 2020-11-30 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2022203854A Pending JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018552196A Expired - Fee Related JP6989136B2 (ja) 2016-04-06 2017-04-05 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022203854A Pending JP2023030082A (ja) 2016-04-06 2022-12-21 Amlおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Country Status (19)

Country Link
US (10) US10596240B2 (enExample)
EP (2) EP4219524A3 (enExample)
JP (3) JP6989136B2 (enExample)
KR (2) KR102411975B1 (enExample)
CN (1) CN109071605A (enExample)
AU (2) AU2017247607B2 (enExample)
BR (1) BR112018070067A2 (enExample)
CA (1) CA3020162A1 (enExample)
CL (4) CL2018002827A1 (enExample)
CO (1) CO2018011889A2 (enExample)
CR (1) CR20180530A (enExample)
IL (1) IL262081A (enExample)
MA (1) MA44605A (enExample)
MX (1) MX2018012152A (enExample)
MY (1) MY197258A (enExample)
PE (1) PE20181896A1 (enExample)
PH (1) PH12018502108A1 (enExample)
SG (3) SG10202008013TA (enExample)
TW (3) TWI727407B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296881A (en) * 2020-04-14 2022-12-01 Universit? De Montr?Al New antigens specific for acute myeloid leukemia (aml) and their uses
CN115290806B (zh) * 2022-08-01 2024-05-28 宁波工程学院 一种亲水作用和阳离子交换的固相萃取生物胺的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999046276A1 (en) * 1998-03-13 1999-09-16 Genos Biosciences, Inc. Zap-1 tumor associated genes and their uses
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
WO2002066501A2 (en) * 2001-01-02 2002-08-29 Hybrigenics PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005514029A (ja) * 2001-11-07 2005-05-19 マンカインド コーポレイション 抗原提示細胞におけるエピトープ同調
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
AU2004235382A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
EP1806358B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2009036246A2 (en) * 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
GB0721686D0 (en) * 2007-11-05 2007-12-12 Medinnova As Polypeptides
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2458014A1 (en) 2010-09-07 2012-05-30 Rijksuniversiteit Groningen Prognostic markers for acute myeloid leukemia (AML)
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013009818A2 (en) * 2011-07-11 2013-01-17 Gevo, Inc. High-performance ketol-acid reductoisomerases
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US10208086B2 (en) * 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
US9254311B2 (en) * 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
ES2729759T3 (es) * 2012-07-12 2019-11-06 Persimmune Inc Vacunas contra el cáncer personalizadas y terapias celulares inmunitarias adoptivas
EP2917388B1 (en) 2012-11-08 2016-10-05 Roche Diagnostics GmbH Nucleic acids encoding chimeric polypeptides for library screening
CN110078813B (zh) * 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI777194B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(一)
WO2015150491A1 (en) * 2014-04-01 2015-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof
JP2017516752A (ja) * 2014-04-01 2017-06-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 単離されたドナーmhc由来ペプチド及びその使用
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
US10357550B2 (en) * 2016-04-06 2019-07-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers

Similar Documents

Publication Publication Date Title
JP2020191862A5 (enExample)
JP2020198875A5 (enExample)
JP2020182458A5 (enExample)
JP2021101700A5 (enExample)
JP2024041841A5 (enExample)
JP2024099580A5 (enExample)
JP6639233B2 (ja) Mage−a1を認識する高結合活性結合分子
JP2020516681A5 (enExample)
JP2019502360A5 (enExample)
JP2018529320A5 (enExample)
JP2019511214A5 (enExample)
JP2018510628A5 (enExample)
JP2021535900A5 (enExample)
JP2019513005A5 (enExample)
JP2019536426A5 (enExample)
JP2019510465A5 (enExample)
JP2019515650A5 (enExample)
JP2018536383A5 (enExample)
JP2021514178A5 (enExample)
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2020506690A5 (enExample)
JP2018509135A5 (enExample)
JP2021528046A5 (enExample)
JP2022502015A5 (enExample)
JP2022502358A5 (enExample)